Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).

Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).

Item
http://www.wikidata.org/entity/Q42727555
Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian modelsLooking back to the future: predicting in vivo efficacy of small molecules versus Mycobacterium tuberculosisPharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosisSynthesis and antiplasmodial and antimycobacterial evaluation of new nitroimidazole and nitroimidazooxazine derivatives.Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.Carbon-14 radiolabeling and in vivo biodistribution of a potential anti-TB compound.Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.Antituberculosis drug research: a critical overview.Targeting the mycobacterial envelope for tuberculosis drug development.Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB AgentsStructural insights of PA-824 derivatives: ligand-based 3D-QSAR study and design of novel PA824 derivatives as anti-tubercular agents.Synthesis of new generation triazolyl- and isoxazolyl-containing 6-nitro-2,3-dihydroimidazooxazoles as anti-TB agents: in vitro, structure-activity relationship, pharmacokinetics and in vivo evaluation.3-[1-(4-Bromo-phen-yl)eth-oxy]-2,2,5-trimethyl-4-phenyl-3-aza-hexa-ne.Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
P2860

Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).

Item
http://www.wikidata.org/entity/Q42727555
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Synthesis and structure-activi ...... o[2,1-b][1,3]oxazine (PA-824).
@en
Synthesis and structure-activi ...... o[2,1-b][1,3]oxazine (PA-824).
@nl
type
label
Synthesis and structure-activi ...... o[2,1-b][1,3]oxazine (PA-824).
@en
Synthesis and structure-activi ...... o[2,1-b][1,3]oxazine (PA-824).
@nl
prefLabel
Synthesis and structure-activi ...... o[2,1-b][1,3]oxazine (PA-824).
@en
Synthesis and structure-activi ...... o[2,1-b][1,3]oxazine (PA-824).
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Synthesis and structure-activi ...... o[2,1-b][1,3]oxazine (PA-824).
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698